Novo shares tumble by double digits on grim sales outlook

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Novo Nordisk expects sales and profits to shrink substantially in 2026 as competition from Eli Lilly and pricing pressure from the U.S. government chip away at its multibillion-dollar obesity drug business. The news delivered midday Tuesday shook investors and Wall Street analysts, sending Novo shares tumbling by double digits on stock exchanges in the U.S. a ...